By inhibiting LOXL2 and TGF-β signaling, ABI-171 could reduce Snail1 expression and prevent EMT progression, thus mitigating fibrotic tissue development and the pathological collagen deposition seen in IPF. Here, LOXL2 is linked to idiopathic pulmonary fibrosis.